The Novel Coronavirus poses new challenges to G6PD deficient persons.
Medications that are being experimented with and, in some places, used might be of great risk to G6PD deficients.
We list here recent related studies of Corornavirus drugs, some of them are of great risk, others have not been tested yet.
The listed studies are in both English and Italian. No translations are available.

Articles in Italian

• [IMPORTANT] Indicazioni ad interim per una appropriata gestione dell’iposurrenalismo in età pediatrica nell’attuale scenario emergenziale da infezione da SARS-CoV-2 [Gruppo di lavoro ISS Malattie Rare COVID-19] -- Rapporto ISS COVID-19 • n. 24/2020 -- 10 maggio 2020
• [IMPORTANT] Indicazioni ad interim per un appropriato sostegno delle persone con enzimopenia G6PD (favismo) nell’attuale scenario emergenziale SARS-CoV-2 [Gruppo di lavoro ISS Malattie Rare COVID-19] -- Rapporto ISS COVID-19 • n. 14/2020 -- 14 aprile 2020
• AIFA - Sperimentazioni cliniche - COVID-19
• Comunicazione AIFA sull'utilizzo di Clorochina e Idrossiclorochina nella terpia dei pazienti affetti da COVID-19 -- Informazioni di sicurezza
• Covid-19, approvato dall'Aifa l'uso compassionevole di ruxolitinib
• Parere elaborato dall’ISS sull'ozonoterapia
• Impiego della Idrossiclorochina nel trattamento dell'infezione da Sars2 Covid-19
• Parere elaborato da Istituto Superiore di Sanità GdL- Farmaci COVID-19 su Clorochina e Tocilizumab
• Bill and Melinda Gates Foundation: diversi esperimenti
• Covid-19, i farmaci in sperimentazione di cui non si parla: quali i più promettenti?

Articles in English

• Glucose‐6‐phosphate dehydrogenase deficiency and hydroxychloroquine in the COVID‐19 era: a mini review - by Maria Elisabetta Onori, Claudio Ricciardi Tenore, Andrea Urbani, Angelo Minucci.
• [IMPORTANT] Interim guidance for the treating people suffering from G6PD enzyme deficiency (favism) in the current SARS-CoV-2 emergency scenario [ISS COVID-19 Rare Diseases Work Group]
• Triggering of Suicidal Erythrocyte Death by Ruxolitinib
• COVID-19 Drug Therapy - Clinical Drug Information 
  (Tim Smith, PharmD, BCPS; Jennifer Bushek, PharmD; Aimée LeClaire, PharmD, BCPS; Tony Prosser, PharmD)
• National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 clinical management
• A trial evaluating treatments for suspected coronavirus infection in people aged 50 years and above with pre-existing conditions and those aged 65 years and above
• A potential coronavirus vaccine funded by Bill Gates is set to begin testing in people
• Bill Gates is helping fund new factories for 7 potential coronavirus vaccines
• G6PD+SARS-CoV-2 Pathogenesis

Therapeutic Treatments Currently Experimented

• Inovio's INO-4800
• Hydroxychloroquine
• Ruxolitinib
• Ozone therapy
• Chloroquine
• Tocilizumab